See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive evidence that Cosentyx (secukinumab) directly causes reduced responses to inactivated vaccines. However, it is important to note that certain medications, including biologic drugs like Cosentyx, can impact the immune system's response to vaccines [1].

Cosentyx is a human monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), which is involved in the pathogenesis of several immune-mediated diseases [2]. Due to its immunomodulatory effects, it might influence the efficacy of vaccines [1].

A study published in the Journal of Allergy and Clinical Immunology reported that patients treated with secukinumab (Cosentyx) showed reduced responses to inactivated influenza vaccine compared to those not receiving the medication [1]. However, this study does not conclusively prove that Cosentyx is the direct cause of reduced responses to inactivated vaccines.

Healthcare providers should consider the potential impact of Cosentyx on vaccine efficacy when making treatment decisions. The Centers for Disease Control and Prevention (CDC) recommends administering all age-appropriate vaccines, including inactivated vaccines, before starting immunosuppressive therapy, if possible [3].

In summary, while there is some evidence suggesting that Cosentyx may impact the immune response to inactivated vaccines, more research is needed to establish a direct causal relationship. Patients should consult their healthcare providers to discuss the risks and benefits of vaccination while on Cosentyx.

Sources:
[1] https://www.jacionline.org/article/S0091-6749(17)31373-5/fulltext
[2] https://www.drugs.com/cosentyx.html
[3] https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetent-hosts.html

(Note: DrugPatentWatch.com was not used as a source for this answer.)